OVARIAN CANCER: NEW RESEARCH (HORIZONS IN CANCER RESEARCH, VOLUME 19) -- OVARIAN CANCER: NEW RESEARCH (HORIZONS IN CANCER RESEARCH, VOLUME 19) -- Library of Congress Cataloging-in-Publication Data -- Contents -- Preface -- Chapter I: Progress in Ovarian Cancer Research -- Abstract -- Introduction -- Genetic Alterations in Ovarian Cancer -- Acquired Genetic Mutation in Ovarian Cancers -- Ovarian Cancer Susceptibility Genes -- The Role of Polymorphic Genes in Epithelial Ovarian Carcinoma -- Epigenetic Gene Silencing and Ovarian Cancer -- Summary -- References -- Chapter II: Ovulation and Ovarian Surface Epithelial Cancer -- Abstract -- Introduction/Background -- Roles of the Ovarian Epithelium in Ovulation and Wound Repair -- Relationship of Ovulation to Common Epithelial Ovarian Cancer -- Oxidative Damage to DNA of Ovarian Surface Epithelial Cells Affected by Ovulation: Carcinogenic Implication and Prophylaxis -- Conclusion and Additional Considerations -- References -- Chapter III: Ovarian Sertoli-Leydig Cell Tumors with Heterologous Elements -- Introduction -- General Features -- Gross Findings -- Histologic Findings -- Immunohistochemistry -- Differential Diagnosis -- Histogenetic Aspects -- Biologic Behavior and Treatment -- References -- Chapter IV: Interleukin-1 System and Sex Steroid Receptor Gene Expression in Human Endometrial Cancer -- Abstract -- Introduction -- Materials and Methods -- Reverse Transcription Polymerase Chain Reaction -- Results -- Discussion -- References -- Chapter V: Role of Membrane-Associated Serine/Threonine Phosphatase in Ovarian Cancer Cell Survival: Evidence for Minor Role of Apoptosis in Gonadotropin-Releasing Hormone's Antiproliferative Signaling -- Abstract -- Material and Methods -- Cell Cultures -- Isolation of Plasma Membrane -- Statistics -- Results.

Correlation between Decreases in PP2A Activity and Apoptosis Induction -- Effects of GnRH Agonist on PP2A Activity and Cell Viability -- Discussion -- References -- Chapter VI: Docetaxel in Combination with Carboplatin as First-Line Chemotherapy for Patients with Epithelial Ovarian Cancer -- Abstract -- Introduction -- Patients and Methods -- Treatment Plan and Administration -- Patient Evaluation and Clinical Assessments -- Results -- Adverse Effects -- Survival -- Discussion -- References -- Chapter VII: Immunospecific Albumin Microspheresas Delivery System for Cisplatin and 5-Fluorouracil for the Treatment of Ovarian Adenocarcinoma -- Abstract -- Introduction -- Materials and Methods -- Human Serum Albumin Immunomicrospheres -- Drug Release from the Immunomicrospheres -- Clonogenic Assays, Cell Survival Growth Curves and Micronuclei Induction -- The Clonogenic Assay -- Cell Survival Growth Curves -- Micronuclei Induction -- The Tumour Model -- Drug Therapy and Animal Survival Endpoints -- Statistical Analysis -- Results -- Clonogenic Assays -- Cell Survival Growth Curves -- References -- Chapter VIII: Strategies for Improving Outcome in Ovarian Cancer: The Role of Surgery -- Abstract -- The Role of Surgery in the Treatment of Ovarian Carcinomas -- Quality Assurance in Medicine -- Quality Assurance in Hesse, Germany -- The GQH Study and the Analysis of the Dataset of Ovarian Cancer -- General Findings -- Adherence to Treatment Guidelines -- What Do We Have to Learn from the Results? -- Final Remarks -- References -- Article Precis -- Chapter IX: Should Systematic Lymphadenectomy Be Performed in Suboptimally Debulked Patients with Stage III Ovarian Carcinoma? A Degog Study -- Synopsis -- Abstract -- Introduction -- Material and Methods -- Results -- Discussion -- References -- Chapter X: Outcomes for Surgery in Ovarian Cancer -- Abstract -- Outcome.

Processes of Care -- Hospital Characteristics -- Specialty of the Surgeon -- Surgeon's Volume -- Conclusion -- References -- Chapter XI: Do Ascites, Mass Volume and Peritoneal Carcinomatosis Affect Serum CA-125 Levels in Patients with Ovarian Carcinoma? A Different Point of View -- Abstract -- Introduction -- Material and Methods -- Results -- Discussion -- References -- Chapter XII: The Usefulness of Serum CA-125 Levels in the Prediction of Optimal Primary Cytoreduction in Patients with Advanced Ovarian Carcinoma -- Summary -- Introduction -- Material and Methods -- Results -- Discussion -- References -- Chapter XIII: Perceived Risk of Ovarian Cancer, Worry about Ovarian Cancer Risk, and Use of Ovarian Cancer Screening by Women at Risk for Ovarian Cancer -- Abstract -- Perceived Risk of Ovarian Cancer, Worry about Ovarian Cancer Risk, and Use of Ovarian Cancer Screening by Women at Risk for Ovarian Cancer -- Methods -- Measures -- Results -- Conclusions -- References -- Precis -- Chapter XIV: New Strategy for the Treatment of Ovarian Cancer with the Aim to Conquer Chemoresistance -- Abstract -- Introduction -- Chemoresistance Mechanisms and Second-Line Chemotherapy -- Gene Therapy -- Antiangiogenic Gene Therapy with Interleukin-10 (IL-10) Targeted at Peritoneal Dissemination of Ovarian Cancer -- Conclusion -- References -- Chapter XV: Treatment Decision Making in Ovarian Cancer -- Treatment Decision Making in Ovarian Cancer -- Principals Guiding Decision Making -- Methods -- The Patient-Physician Interaction -- Patient-Physician Decision Making Style in Ovarian Cancer -- Communication Skills -- Importance of Information for Women with Ovarian Cancer -- Shared Decision Making -- Benefits of Shared Decision Making -- Decision Aids -- Conclusion -- References -- Index.